Pembrolizumab in MIBC
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing
schedules of cemiplimab given in combination with cisplatin and docetaxel induction
chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head ...
Age: 18 years - 66+
Gender: All
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, efficacy, PK and
pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will
consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Par...
Age: 18 - 99 years
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or
Metastatic Solid Tumors
Age: 18 years - 66+
Gender: All
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482)
plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the
adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
...
Age: 18 years - 66+
Gender: All
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
The purpose of this study is to assess the safety and efficacy of treatment with
pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with
mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not
...
Age: 18 years - 66+
Gender: Female
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in
participants with advanced (metastatic and/or unresectable) solid tumors.
Age: 18 years - 66+
Gender: All
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386
in combination with pembrolizumab in participants with previously treated selected solid
tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination ...
Age: 18 years - 66+
Gender: All
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Age: 18 years - 66+
Gender: All
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination
with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide
versus standard therapy alone for the treatment of poorly differentiated extrapulmo...
Age: 18 years - 66+
Gender: All
Dupilumab_Metastatic NSCLC
This is an Phase Ib/2 study, single arm, single cohort study to determine the safety and
tolerability of Dupilumab with PD-(L)1 blockade for patients with relapsed/refractory
metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
This phase II trial tests the effect of atezolizumab given with usual chemotherapy during
radiation therapy in treating patients with superior sulcus non-small cell lung cancer.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immu...
Age: 18 years - 66+
Gender: All
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare
the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with
chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal c...
Age: 12 - 75 years
Gender: All
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
This phase II trial studies the side effects of chemotherapy and intensity modulated
radiation therapy in treating patients with low-risk HIV-associated anal cancer, and
nivolumab after standard of care chemotherapy and radiation therapy in treating patients with
...
Age: 18 years - 66+
Gender: All
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
This phase II/III trial compares the addition of radiation therapy to the usual treatment
(immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating
patients with non-small cell lung cancer that has spread to nearby tissue or lymph n...
Age: 18 years - 66+
Gender: All
A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study is being done to see if a drug called disitamab vedotin, alone or with
pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe
the drug is for participants.
Participants will have cancer that has spread in the body ...
Age: 18 years - 66+
Gender: All
Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma
The study consists of Safety Run-in and Phase 2 Cohorts.
The primary objectives of the safety run-in cohorts of this study are to evaluate the safety,
tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with
pembrolizumab + 5-fluoroura...
Age: 18 years - 66+
Gender: All
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of
ZEN003694 when given in combination with nivolumab with or without ipilimumab in treating
patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blockin...
Age: 18 years - 66+
Gender: All
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical
activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with
metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more pr...
Age: 18 years - 66+
Gender: Male